Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioPhausia AB Sells Generics Business | Contract Pharma

What are you searching for?

Sign in
Breaking News

BioPhausia AB Sells Generics Business

To focus on commercial development of proprietary and imported products

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Medivir subsidiary, BioPhausia, has reached an agreement to sell its generics business, BMM Pharma, to Bluefish Pharmaceuticals for $4.1 million plus inventories valued at approximately $1.9 million. BMM Pharma’s staff will not transfer in the acquisition. Medivir is a research-based specialty pharmaceutical company focusing on infectious diseases.

“This deal is a natural last step in the concentration and focus of BioPhausia’s business, which began about a year ago. We will now be focusing on the ongoing commercial development of our Proprietary Products and Parallel Imported Products,” said Maris Hartmanis, chief executive office of BioPhausia.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters